Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Differences in hormone therapy for patients with advanced metastatic prostate cancer

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 700

Prof Axel Merseburger - University Hospital Schleswig-Holstein, Lübeck, Germany

Prof Axel Merseburger speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the differences between the multiple forms of androgen deprivation therapy (ADT) that are available.

Prof Merseburger explains the advantages and disadvantages associated with the use of LHRH agonists versus LHRH antagonists and how these can be applied to the clinic.

He also mentions the PRONOUNCE trial, which aims to assess the occurrence of cardiovascular events among patients receiving ADT.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation